- Home
- Companies
- Kiadis Pharma NV
- Products
- Model K-NK002 - NK Cells for Cancer ...
Model K-NK002 - NK Cells for Cancer Immunotherapeutics
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical Trial Network (BMT CTN), which consists of the premier transplant centers in the United States.
Kiadis’ NK-cell program consists of off-the-shelf and haplo donor cell therapy products for the treatment of liquid and solid tumors. Our proprietary off-the-shelf NK-cell platform is based on NK-cells from a unique universal donor, expanded and activated ex vivo using our PM21 particle technology. The Kiadis off-the-shelf platform has the potential to make NK-cell therapy products rapidly and economically available for a broad patient population across a potentially wide range of indications.